GENBNasdaqPharmaceutical PreparationsFiscal year ends December 31

Generate Biomedicines, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$12.56+0.47 (+3.89%)

Close on Oct 19, 2026

Market cap: $1.61B
P/E (TTM): –
Dividend yield: –

Generate Biomedicines, Inc. balance sheet

Millions of USD, except per-share data. Shares in millions.

Line item	Q2 2026 2026-06-30	Q1 2026 2026-03-31	Q4 2025 2025-12-31	Q2 2025 2025-06-30	Q1 2025 2025-03-31	Q4 2024 2024-12-31
Cash & Equivalents	135	161	122	154	221	–
Short-Term Investments	322	356	100	–	–	–
Cash & Short-Term Investments	457	517	221	154	221	–
Prepaid Expenses & Other	13	19	13	–	–	–
Total Current Assets	470	535	234	–	–	–
Property, Plant & Equipment	27	28	29	–	–	–
Gross Property, Plant & Equipment	82	79	77	–	–	–
Accumulated Depreciation	-55	-52	-48	–	–	–
Operating Lease Right-of-Use Assets	55	58	60	–	–	–
Other Long-Term Assets	9.06	4.75	6.81	–	–	–
Total Assets	562	626	330	–	–	–
Accounts Payable	5.65	7.62	3.84	–	–	–
Current Portion of Leases	9.88	10	11	–	–	–
Deferred Revenue (Current)	12	17	21	–	–	–
Other Current Liabilities	2.52	2.42	2.63	–	–	–
Total Current Liabilities	57	58	82	–	–	–
Long-Term Leases	48	49	51	–	–	–
Operating Lease Liabilities	58	59	61	–	–	–
Other Long-Term Liabilities	0	0	0.12	–	–	–
Total Liabilities	106	111	142	–	–	–
Common Stock	0.13	0.13	0.03	–	–	–
Additional Paid-In Capital	1,261	1,252	60	–	–	–
Retained Earnings	-805	-738	-676	–	–	–
Comprehensive Income & Other	-0.13	0.02	0.11	–	–	–
Shareholders' Equity	456	515	-616	-518	-471	-435
Noncontrolling Interest	0	0	-7.23	–	–	–
Total Equity	456	515	-616	-518	-471	-435
Total Liabilities & Equity	562	626	330	–	–	–
Shares Outstanding(shares)	128	128	33	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: –

Financial strength

Current ratio: 8.30
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 239.0%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 3.53
Dividend yield: –